NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis $9.01 -0.31 (-3.33%) Closing price 03:58 PM EasternExtended Trading$9.02 +0.01 (+0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Design Therapeutics Stock (NASDAQ:DSGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Design Therapeutics alerts:Sign Up Key Stats Today's Range$8.96▼$9.5750-Day Range$9.32▼$14.6352-Week Range$7.82▼$17.25Volume281,932 shsAverage Volume573,654 shsMarket Capitalization$577.00 millionP/E RatioN/ADividend YieldN/APrice Target$18.57Consensus RatingModerate Buy Company Overview Design Therapeutics is a clinical-stage biotechnology company developing medicines for inherited diseases. Its research focuses on conditions associated with genetic repeat expansions, in which repeated DNA sequences can disrupt the normal activity of a gene. The company’s GeneTAC platform is designed to create small molecules that interact with these expanded genetic sequences and help restore gene expression. Design Therapeutics aims to use this approach to address the underlying causes of disease rather than only manage symptoms. Its pipeline includes DT-216, an investigational candidate being developed for Friedreich ataxia, a rare inherited disorder associated with reduced production of frataxin. Design Therapeutics is based in California and has focused its drug-development work on genetic diseases with significant unmet medical needs.AI Generated. May Contain Errors. Read More Design Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreDSGN MarketRank™: 2.632409440175 of 5 starsDesign Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 448th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingDesign Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDesign Therapeutics has a consensus price target of $18.57, representing about 106.1% upside from its current price of $9.01.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.89% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 16.22, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently decreased by 5.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentDesign Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Design Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.10% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DSGN Stock News HeadlinesRBC Cuts Price Target on Design Therapeutics to $19 From $20, Keeps Outperform, Speculative RiskNovember 5, 2026 | marketscreener.comMDesign Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 20 at 1:00 AM | Paradigm Press (Ad)Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business UpdatesNovember 4, 2026 | finance.yahoo.comDesign Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027October 4, 2026 | seekingalpha.comWells Fargo Initiates Design Therapeutics at Overweight With $26 Price TargetOctober 2, 2026 | marketscreener.comMDesign Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare ConferenceSeptember 2, 2026 | globenewswire.comRBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)August 31, 2026 | theglobeandmail.comSee More Headlines DSGN Stock Analysis - Frequently Asked Questions How have DSGN shares performed this year? Design Therapeutics' stock was trading at $9.38 at the start of the year. Since then, DSGN stock has decreased by 3.9% and is now trading at $9.01. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' top institutional shareholders include Baker BROS. Advisors LP (4.67%), State Street Corp (2.61%), Goldman Sachs Group Inc. (0.93%) and Almitas Capital LLC (0.93%). Insiders that own company stock include John P Schmid, Deepa Prasad and Arsani William. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, DSGN's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DSGN CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees60Year Founded2017Price Target and Rating Average Price Target for Design Therapeutics$18.57 High Price Target$26.00 Low Price Target$14.00 Potential Upside/Downside+106.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.51% Return on Assets-33.35% Debt Debt-to-Equity RatioN/A Current Ratio16.78 Quick Ratio16.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book2.85Miscellaneous Outstanding Shares64,040,000Free Float53,086,000Market Cap$577.00 million OptionableOptionable Beta1.73 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:DSGN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | SponsoredWashington's deadline. Elon's problem.On January 1, 2027, Washington raises the outside-China sourcing requirement for grid battery projects seeking...Behind the Markets | SponsoredThe One-Ticker Retirement BoostA $10,000 investment at its 1998 start would be worth over $630,000 today, roughly 6X the S&P 500 over the sam...The Oxford Club | SponsoredShould I sell? $84 off ends Dec 9A stock you own drops 20%, and you're asking yourself: should I sell? Seeking Alpha Premium gives you a second...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.